Glial role in oxaliplatin-induced neuropathic pain

@article{Mannelli2014GlialRI,
  title={Glial role in oxaliplatin-induced neuropathic pain},
  author={L. Mannelli and A. Pacini and L. Micheli and A. Tani and M. Zanardelli and C. Ghelardini},
  journal={Experimental Neurology},
  year={2014},
  volume={261},
  pages={22-33}
}
Oxaliplatin, a platinum-based chemotherapeutic agent, has become a standard treatment for advanced colorectal cancer. The dose-limiting toxicity of this compound is the development of peripheral neuropathy. A tangled panel of symptoms, sensory loss, paresthesia, dysesthesia and pain, may be disabling for patients and adversely affect their quality of life. Recently, we described a characteristic glial activation profile in a rat model of oxaliplatin-induced neuropathy. Glial cells are… Expand
Niclosamide Inhibits Oxaliplatin Neurotoxicity while Improving Colorectal Cancer Therapeutic Response
Therapeutic Agents for Oxaliplatin-Induced Peripheral Neuropathy; Experimental and Clinical Evidence
Management of Oxaliplatin-Induced Peripheral Sensory Neuropathy
Oxaliplatin-induced peripheral neuropathy: clinical features, mechanisms, prevention and treatment
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 69 REFERENCES
Neuropathic pain in cancer.
  • M. Fallon
  • Medicine
  • British journal of anaesthesia
  • 2013
...
1
2
3
4
5
...